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Deposition of transthyretin (TTR) amyloid is a pathological hallmark of familial amyloidotic polyneuropathy (FAP). Recently we showed that
TTR binds to membrane lipids via electrostatic interactions and that membrane binding is correlated with the cytotoxicity induced by
amyloidogenic TTR. In the present study, we examined the role of lipid composition in membrane binding of TTR by a surface plasmon resonance
(SPR) approach. TTR bound to lipid bilayers through both high- and low-affinity interactions. Increasing the mole fraction of cholesterol in the
bilayer led to an increase in the amount of high-affinity binding of an amyloidogenic mutant (L55P) TTR. In addition, a greater amount of L55P
TTR bound with high affinity to membranes made from anionic phospholipids, phosphatidylglycerol (PG) and phosphatidylserine (PS), than to
membranes made from zwitterionic phospholipid phosphatidylcholine (PC). The anionic phospholipids (PS and PG) promoted the aggregation of
L55P TTR by accelerating the nucleation phase of aggregation, whereas the zwitterionic phospholipid PC had little effect. These results suggest
that cholesterol and anionic phospholipids may be important for TTR aggregation and TTR-induced cytotoxicity.
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Neurodegenerative diseases associated with amyloidosis
involve the build-up of proteinaceous deposits in the extracel-
lular compartment of the nervous system [1,2]. Although the
amyloidogenic proteins in their native state have little similarity
in structure and perform different biological functions, theAbbreviations: Aβ, β-amyloid protein; AFM, atomic force microscopy; DLS,
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tidylethanolamine; PG, dimyristoyl-L-α-phosphatidylglycerol; PrP, prion protein;
PS, dimyristoyl-L-α-phosphatidylserine; RU, response unit; SM, sphingomyelin;
SPR, surface plasmon resonance; SUVs, small unilamellar vesicles; T4, thyroxine;
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doi:10.1016/j.bbamem.2007.09.018common structure of amyloid fibrils has led to the suggestion
that the mechanisms of protein aggregation and neurotoxicity
may be similar for different amyloidoses [3–5].
Familial amyloidotic polyneuropathy (FAP) is a fatal hereditary
neuropathy characterized by systemic deposition of amyloid
formed from misfolded transthyretin (TTR) [6,7], a transporter
protein for thyroxine (T4) and retinol in the plasma and the brain
[8]. Native TTR consists of four identical subunits, each containing
127 amino-acid residues which form a predominantly β-sheet
structure [9]. A large number of mutations have been identified in
TTR, most of which cause amyloidosis [7,10]. It has been
suggested that amyloidogenic mutations destabilize the tetrameric
structure of TTR, leading to the formation of an amyloidogenic
intermediate (probably a TTR monomer) which can self-assemble
to form amyloid [11,12]. Although the mechanisms of TTR-
induced cytotoxicity are still poorly understood, previous studies
have reported that amyloidogenic TTR may cause its cytotoxic
effects by disrupting intracellular Ca2+ homeostasis [13], inducing
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inflammatory cytokines [15]. Several studies have identified TTR
oligomers as the major form of TTR that cause cytotoxicity
[13,16].
Recently, we reported that TTR binds predominantly to lipids
in the plasmamembrane via electrostatic interactions, and that this
binding is correlated with the cytotoxic effect of amyloidogenic
TTR [17]. Previous studies of other amyloidogenic proteins have
also shown that binding to lipids in the plasma membrane is an
important step in the aggregation and cytotoxicity [18,19]. It has
been suggested that binding to membrane lipids may induce
proteinmisfolding and aggregation by providing a favorable local
environment [20–22]. Variations in lipid composition of the
membrane can modify the protein–lipid interactions. For
example, the concentration of cholesterol is correlated with the
membrane binding of amyloidogenic proteins, such asβ-amyloid
protein (Aβ) [19,23] and prion protein (PrP) [18]. Cholesterol has
also been identified as a major component of the lipids that are
associated with various amyloid deposits [24]. It has been
suggested that membrane-bound Aβ [25] or PrP [26] may act as a
nucleus for aggregation. By modulating the organization of the
plasma membrane, cholesterol may contribute to the aggregation
[27–29] and cytotoxicity [18,19,27] of amyloidogenic proteins.
In addition, anionic phospholipids have also been reported to be
involved in the binding of some amyloidogenic proteins
[22,30,31]. It is not known which lipid species in the membrane
preferentially bind TTR, and how lipid composition influences
this binding.
In the present study, the effects of cholesterol and different
phospholipids on the binding and aggregation of TTR were
studied. We show that the binding of an amyloidogenic TTR
mutant, L55P TTR, to phospholipid bilayers is influenced by both
the concentration of cholesterol and type of phospholipids in the
membrane. We also show that anionic phospholipids promote the
aggregation of L55PTTR. These results suggest that alterations in
membrane lipid composition may play a role in the aggregation
and cytotoxicity of TTR.
2. Materials and methods
2.1. Materials
Thewild-type (WT)TTR and a highly amyloidogenicmutant, L55PTTR,were
expressed in Escherichia coli and the native tetramers purified using ion-exchange
and size-exclusion chromatography to a purity of N95% [17]. Dimyristoyl-L-α-
phosphatidylcholine (PC), dimyristoyl-L-α-phosphatidylserine (PS), dimyristoyl-
L-α-phosphatidylglycerol (PG), and dimyristoyl-L-α-phosphatidylethanolamine
(PE) were purchased from Avanti Polar Lipids (Alabaster, AL). Highly oriented
pyrolytic graphite (HOPG) of ZYB quality was the product of Advanced Ceramics
(Cleveland, OH). Sphingomyelin (SM) and cholesterol were purchased from
Sigma-Aldrich (Castle Hill, NSW, Australia).
2.2. Preparation of liposomes from phospholipids
Artificial liposomeswith different compositions were prepared as described in
a previous study [17]. Briefly, the lipids were dissolved in chloroform/methanol
(3:1, v/v) at a concentration of 2 mM. Lipid mixtures were prepared with a
composition based on that of the grey matter of human brain [32], except that the
cholesterol concentration was 0, 25 or 50% on a molar basis of the total lipids,
while the remaining lipids were in a constant molar ratio of 6:5:2:2 (PC:PE:PS:SM). The lipids were dried under a constant flow of N2 gas, and then in vacuo
overnight, to create a uniform lipid film which can form liposomes by hydration.
The dried lipids were resuspended in 20 μMphosphate buffer (pH 7.4) containing
150 mM NaCl to a final concentration of 1 mM. After sonication for 30–60 min,
the lipid suspension was extruded seventeen times through a polycarbonate filter
membrane (50 nm pore size) using a LiposoFast extruder (Avestin, Ottawa,
Canada) to produce unilamellar liposomes which were 50±4 nm in diameter as
determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS
(Malvern Instruments, Malvern, UK). These small unilamellar vesicles (SUVs)
were later used to prepare a lipid bilayer on the surface of biosensor chips for
membrane binding studies [17,33].
2.3. Surface plasmon resonance analysis of membrane binding
The binding of TTR to lipid bilayers was studied in real time by surface
plasmon resonance (SPR) using a Biacore 3000 biosensor (Biacore AB, Uppsala,
Sweden) and was performed essentially as described previously [17]. Artificial
liposomes were immobilized onto the surface of an L1 biosensor chip to form a
lipid bilayer. TTR preparations (100 μl, in 20 mM phosphate buffer containing
150 mM NaCl, pH at 7.4) were centrifuged at 15,000×g for 1 min to remove
insoluble materials, and then applied to the lipid bilayer at a flow rate of 30 μl/min
for 200 s. The running buffer used was 20 mM phosphate buffer (pH 7.4)
containing 150 mM NaCl. A 10-min wash by the running buffer was performed
after each injection to allow for dissociation of TTR. The lipid bilayer was then
regenerated by an injection ofNaOH (10μLof a 10-mMsolution) at 50μl/min. The
amount of binding was determined by changes in the instrumental response unit
(RU). As described previously [17], the amount of binding at equilibrium (Req),
which represents the maximum binding of TTR at a given concentration, was
calculated. The binding data were then analyzed using Scatchard plots in whichReq
was plotted against Req/C (where C=TTR concentration). Although TTR
preparations at different aging times contained various forms of the protein with
disparate molecular masses, TTR concentrations in all preparations were calculated
by assuming that all TTR molecules were present as tetramers.
2.4. Analysis of TTR aggregation by solution turbidity assay and dynamic
light scattering
TTR aggregation was monitored by changes in solution turbidity and particle
size as TTR was incubated (aged) at 37 °C in various solutions. As described
previously [13], solution turbidity was monitored by measuring the absorbance of
the solution at a wavelength of 330 nm using a SmartSpec 3000 spectrophotometer
(Bio-Rad,Hercules, CA). Changes in particle sizeweremeasured bymeans of DLS
using a Zetasizer Nano ZS [13].
2.5. Atomic force microscopy
Atomic force microscopy (AFM) was used to examine changes in TTR
morphology during the time course of aggregation and was performed as described
in a previous study [13]. TTR solutions (20 μl, 0.1–1 μM) were deposited on a
freshly cleavedHOPG surface and incubated at 37 °C for 30min. After five washes
with deionized distilled water, the HOPG surface was then dried under a constant
flow of N2 gas. TTR samples were examined by a Digital Instruments Nanoscope
IV Multimode scanning probe microscope (Veeco Instruments, Woodbury, NY).
NSC15 125μmsilicon cantileverswith a tip length of 15μm(Mikromasch, Tallinn,
Estonia) were used for data acquisition. Images were obtained in the tapping mode
at oscillation frequencies of 200–300 kHz with constant adjustment of the force
exerted on the cantilever. AFM images were analyzed by the WSxM 4.0 software
(Nanotec Electronica S.L., Madrid, Spain).3. Results
3.1. Effect of cholesterol on membrane binding of TTR
As previous studies have shown that cholesterol can increase
the binding of Aβ to lipid membranes [19,28], we first examined
Fig. 1. (A) Sensograms of TTR (2.5 μM, aged at 37 °C for 7 days) binding to immobilized lipid bilayers made from lipid mixtures containing 0% (solid lines), 25%
(dashed lines) and 50% cholesterol (dotted lines). TTR was applied for 200 s before a 10-min wash-off to allow for dissociation. The amount of binding was measured
by changes in RU. (B) Scatchard plots of the binding between TTR (0.1–40 μM, aged at 37 °C for 7 days) and lipid bilayers made from lipid mixtures containing 0%
(□, solid lines), 25% (○, dashed lines) and 50% (▵, dotted lines) cholesterol. Values are means±SEM (n=4).
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lesterol concentrations by an SPR biosensor system. Liposomes
made from lipid mixtures containing 0%, 25% or 50% cholesterol
were immobilized onto the surface of an L1 biosensor chip to
create a lipid bilayer. TTR preparations (0.1–40 μM, aged at
37 °C for 7 days) were then applied to the lipid bilayers. The
amount of binding at equilibrium (Req), which denotes theFig. 2. Scatchard plots of the binding between TTR (0.3–40 μM, aged at 37 °C for
dashed lines) and PS (▵, dotted lines). Values are means±SEM (n=4).theoretical maximum amount of binding, was calculated from
the known data as previously described [17].
Similar to the binding of TTR to the plasma membrane
[17], TTR was found to bind reversibly to the lipid
membranes (Fig. 1A). Scatchard plot analysis (Req vs. Req/
C) of TTR binding (Fig. 1B) indicated the presence of both
high- and low-affinity interactions between TTR and the7 days) and homogeneous lipid bilayers made from PC (□, solid lines), PG (○,
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affinity binding for all the TTR variants were in the order of 10−5
M. For the high-affinity binding, the KD of WT TTR was in the
order of 10−6 M, while the KD of L55P TTR binding to the lipid
bilayers was approximately 10−7 M (Fig. 1B). These KD values
were similar to those observed in our previous studies for TTR
binding to the plasma membrane [17].
Scatchard plots of TTR binding to the lipid membranes also
showed that varying membrane cholesterol concentration had no
significant effect on the amount of binding for WT TTR. How-
ever, increasing the membrane cholesterol concentration was asso-
ciated with greater amount of high-affinity binding for L55P TTR
(Fig. 1B).Fig. 3. Aggregation of TTR determined by solution turbidity measured as absorbance a
(▪, black solid lines) TTR (2 μM) were aged in 20 mM phosphate buffer (pH 7.4) co(C) Analysis of TTR aggregation by AFM. WT and L55P TTR were examined at 0, 3
observed over the time of ageing. All the WT TTR preparations were predominantly co
L55P TTR preparation contained similar structures to those in the WT TTR preparation
were observed in the L55P TTRpreparation after ageing for 3 days (v). After ageing for 7
L55P TTR preparation along with the amorphous TTR aggregates (vi).3.2. Binding between TTR and phospholipids
To examine the role of individual phospholipids in the binding
of TTR to lipid membranes, homogenous phospholipid bilayers
made from PS, PG or PC were used for binding assays. The
binding of TTR (0.3–40 μM, aged at 37 °C for 7 days) to the
phospholipid bilayers was examined. As observed with mem-
branes made from the cholesterol-containing lipid mixtures, TTR
bound to bilayers of individual phospholipids via both high- and
low-affinity interactions (Fig. 2). TheKD values of high- and low-
affinity interactions between TTR and the phospholipids were
similar to those determined for the interactions between TTR and
the cholesterol-containing lipid mixtures. For L55P TTR, at a wavelength of 330 nm (A) and DLS (B). WT (□, grey dashed lines) and L55P
ntaining 150 mM NaCl at 37 °C for 12 days. Values are mean±SEM (n=3–4).
and 7 days of ageing. For WT TTR, no significant changes in morphology were
mprised of globular structures ∼20 nm in diameter (i, ii and iii). Before aging, the
s (iv). Larger amorphous TTR aggregates with a diameter of approximately 50 nm
days, fibrillar structures with an apparent diameter of∼20 nmwere observed in the
Fig. 4. Effect of phospholipids on TTR aggregation examined by solution
turbidity measured as absorbance at a wavelength of 330 nm (A330). WT (empty
symbols) and L55P TTR (filled symbols) (10 μM) were aged at 37 °C over
7 days in the presence of liposomes made from DMPC (○ and ●), DMPG (▿
and ▾) and DMPS (▵ and ▴) at a concentration of 500 μM. In the control
incubation (Ctrl) TTR was aged in the absence of phospholipids (□ and ■).
Values are means of multiple measurements (n=3–4, SEM smaller than 10% of
the means).
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membranes made from anionic phospholipids (PG and PS) than
the membranes made from zwitterionic PC (Fig. 2). The amount
of high-affinity binding of L55P TTR to the phospholipids
showed a relative order of PSNPGNPC.
3.3. Effect of phospholipids on TTR aggregation
To explore the effect of phospholipids on the aggregation of
TTR, aggregation of TTR in solution was studied first. TTR
(2 μM) was incubated in 20 mM phosphate buffer (pH 7.4)
containing 150 mM NaCl at 37 °C for up to 12 days. TTR
aggregation was monitored by solution turbidity (absorbance at
a wavelength of 330 nm, A330) (Fig. 3A) and by DLS (Fig. 3B).
No aggregation occurred in theWT TTR preparations during the
time course of aging. For L55P TTR, both solution turbidity and
DLS measurements showed a similar pattern of aggregation,
including an initial increase in aggregation during the first day of
ageing, followed by a stable phase lasting approximately 3 days
in which there was little apparent increase in aggregation, and a
continuous increase in aggregation thereafter. This biphasic
pattern of aggregation is typical of a nucleation-dependent
polymerization process which is common for the aggregation of
many amyloidogenic proteins [13,34]. The average particle size
in the stable phase as determined by DLS was approximately
30 nm.
TTR preparations at different times of aging were analysed by
AFM to determine the morphological changes during aggregation
(Fig. 3C). WT TTR exhibited a relatively constant morphology
over the 7 days of aging. All the WT TTR preparations contained
predominantly globular structures with an apparent diameter of
approximately 20 nm, which are consistent in size with TTR
tetramers [13]. Before aging, the L55P TTR preparation also
predominantly contained structures with similar size to TTR
tetramers. After aging for 3 days, irregular structures with a
diameter of approximately 50 nm were observed in the L55P TTR
preparation. Previous studies have shown that these amorphous
aggregates are likely to be TTR oligomers [13]. After aging for
7 days, some fibrillar structures with an apparent diameter of
approximately 20 nmwere observed in the L55P TTR preparation
in addition to the amorphous aggregates.
To examine whether binding of TTR to phospholipids
influences TTR aggregation, WT and L55P TTR (10 μM) were
aged at 37 °C for up to 7 days in 20 mM phosphate buffer (pH
7.4) containing 150 mM NaCl in the presence of liposomes
(500 μM) made from PC, PG or PS. Since the presence of
liposomes prevented accurate measurement of changes in the
size of protein molecules by DLS or AFM (data not shown),
aggregation of TTR was monitored by solution turbidity as
measured by the absorbance at a wavelength of 330 nm (A330)
(Fig. 4).
No significant increase in solution turbidity was observed in the
WT TTR preparation either in the absence or the presence of
phospholipids. In the absence of phospholipids, L55P TTR
aggregated via a similar pattern to that described above (at a shorter
time scale due to the higher TTR concentration). Incubation with
PC did not significantly change the aggregation kinetics of L55PTTR, whereas PG and PS promoted TTR aggregation by
significantly accelerating the initial nucleation phase of aggrega-
tion. The effect on L55P TTR aggregation showed a relative order
of PSN PGNPC (Fig. 4), consistent with their relative binding
capacities for L55P TTR.
4. Discussion
As binding of TTR to lipids in the plasma membrane is closely
associated with its cytotoxic effects [17], the present study was
undertaken to examine the role of individual lipids in the mem-
brane binding and aggregation of TTR. This study demonstrates
that TTR binding to lipid membranes is influenced by the compo-
sition of the membrane, suggesting that lipid composition may be
important for the regulation of TTR aggregation and TTR-induced
cytotoxicity.
Previous studies have reported that cholesterol concentration is
correlated with the membrane binding of Aβ [19,25]. In the pres-
ent study, binding between amyloidogenic TTR and lipid mem-
branes containing different cholesterol concentrations showed that
increasing the cholesterol concentration was associated with
greater amount of high-affinity binding, indicating that an increase
in membrane cholesterol concentration is associated with more
high-affinity binding sites for TTR within the membrane. As TTR
binds to membrane lipids through electrostatic interactions [17],
the lack of charged groups in cholesterol makes it unlikely that
cholesterol binds directly to TTR. As a modulator of membrane
fluidity and rigidity [35], cholesterol is known to change the
packing and orientation of phospholipids in themembrane [35,36].
Therefore, cholesterol could modulate the membrane binding of
amyloidogenic proteins by changing the packing or orientation of
phospholipids in the membrane [19,23,37,38]. In the case of TTR
binding, cholesterol may promote the interaction between
amyloidogenic TTR and phospholipids by altering the orientation
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membrane.
The present study also show that a greater amount of L55P
TTR bound via high-affinity to the anionic phospholipids (PG
and PS) than to the zwitterionic phospholipid (PC), consistent
with the view that TTR binds to the membrane via electrostatic
interactions [17]. It has been suggested that electrostatic
interactions are likely to occur between the negatively charged
headgroups of anionic phospholipid and positively charged
residues in TTR molecules [30]. The electrostatic interactions
between anionic phospholipids and TTR may provide a
favourable environment for amyloidogenesis. For example,
anionic phospholipids may produce an acidic local environment
[30], which can induce aggregation of the protein [39,40].
Anionic phospholipids have been reported to induce confor-
mational conversion of Aβ [41] and PrP [31] to form β-sheet-
enriched amyloidogenic structures.
Studies of TTR aggregation kinetics showed that TTR
aggregated in a non-linear sigmoidal fashion, typical of a
nucleation-dependent polymerization process where the initial
stable phase corresponds to the nucleation phase [34,42]. In the
present study, aging of L55P TTR in the presence of anionic
phospholipids resulted in a significant acceleration of the initial
nucleation phase of aggregation. Therefore, anionic phospho-
lipids may promote TTR aggregation by increasing the rate of
nucleation. Morphological studies using AFM showed that the
nucleation phase of L55P TTR aggregation was associated with
the formation of amorphous oligomeric structures, suggesting
that the nucleation process may involve oligomerization of
TTR. Formation of oligomers (or protofibrils) prior to the
appearance of mature amyloid fibrils has also been reported for
other amyloidogenic proteins [43,44]. Thus, anionic phospho-
lipids may promote the formation of TTR oligomers.
The studies reported here indicate that the lipid composition
of the membrane play an important role in TTR binding.
Cholesterol is enriched in certain microdomains in the plasma
membrane known as lipid rafts [45]. It is now understood that
the organization of lipids in the membrane is important for
signal transduction as membrane receptors and ion channels are
preferentially located in these lipid rafts [46,47]. Previous
studies have shown that binding of amyloidogenic proteins to
lipid rafts may induce their aggregation [26,48,49]. Analysis of
the lipids associated with different types of amyloid deposits has
shown that the amyloids possess a similar lipid composition to
that of lipid rafts [24]. In addition, studies of amyloid formation
in vitro have shown that the association with lipid rafts only
occurs at the early stages of amyloidogenesis [24], suggesting
that binding to lipid rafts may contribute to amyloidogenesis by
inducing conformational changes and aggregation of amyloido-
genic proteins. Thus it is possible that TTR also binds
preferentially to lipid rafts in the plasma membrane.
It is known that phospholipids are distributed across plasma
membranes of eukaryotic cells in an asymmetrical manner, with
PS predominantly present in the cytoplasmic leaflet [50]. The
asymmetrical distribution of phospholipids is maintained by a
variety of transporters including flippase, floppase and scramblase
[51]. Although the transmembrane phospholipid asymmetry canbe disrupted by membrane disruption, this is unlikely to be the
mechanism by which TTR comes into contact with PS as our
previous studies have shown that TTR does not induce membrane
disruption [13]. Alternatively, it has been reported that surface
exposure of PS can be induced by Ca2+ influx which alters the
activities of transmembrane phospholipid transporters [52,53]. It
is possible that surface exposure of PS is induced byCa2+ influx in
neuronal cells.
Previous studies have shown that oligomers are likely to be the
major form of TTR causing cytotoxic effects [13,16]. Binding of
TTR oligomers to lipid rafts could be involved in the induction of
TTR cytotoxicity. Our group recently reported that TTR olig-
omers can disrupt intracellular Ca2+ homeostasis by inducing an
influx of Ca2+ via voltage-gated Ca2+ channels (VGCCs) [13]. In
addition, the negatively charged groups (e.g. phosphodiester) of
anionic phospholipids have been shown to be involved in the
regulation of the activity of VGCCs [54]. Therefore, we speculate
that cholesterol and anionic phospholipids may be involved in the
aggregation and cytotoxicity of amyloidogenic TTR by modulat-
ing its binding to lipid rafts.
In summary, the present study shows that cholesterol and
anionic phospholipids can promote the membrane binding of
amyloidogenic TTR. As binding to membrane lipids is likely to
be a key step in the induction of TTR cytotoxicity, this study
suggests that membrane lipid composition may influence TTR
cytotoxicity. These findings also suggest that membrane lipids
may be novel targets for the development of therapeutic strate-
gies for FAP. For example, lowering cholesterol by inhibiting its
synthesis using lovastatin has been shown to reduce not only the
membrane binding of Aβ but its cytotoxic effects on neuronal
cells [19]. Indeed, drugs that reduce cholesterol (e.g. lovastatin
and simvastatin) have been shown to attenuate the neuropath-
ological changes of Alzheimer's disease [55,56]. Whether these
drugs might also be used for the treatment of FAP needs to be
explored in future studies.
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